Cargando…

R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma

To further explore the role of rituximab when added to the CHOP-like regimen in the treatment of immunohistochemically defined non-germinal center B-cell subtype (non-GCB) diffuse large B-cell lymphoma (DLBCL), 159 newly diagnosed DLBCL patients were studied retrospectively based on the immunohistoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Xiao-Hui, Li, Bo, Yang, Sheng, Lu, Ning, Zhang, Xun, Zou, Shuang-Mei, Li, Ye-Xiong, Song, Yong-Wen, Zheng, Shan, Dong, Mei, Zhou, Sheng-Yu, Yang, Jian-Liang, Liu, Peng, Zhang, Chang-Gong, Qin, Yan, Feng, Feng-Yi, Shi, Yuan-Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sun Yat-sen University Cancer Center 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777489/ https://www.ncbi.nlm.nih.gov/pubmed/22640627 http://dx.doi.org/10.5732/cjc.011.10420

Ejemplares similares

Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients
por: Huang, Ying, et al.
Publicado: (2012)

P1186: RETROSPECTIVE STUDY: ZANUBRUTINIB COMBINED WITH R-CHOP OR R-CHOP REGIMEN IN THE TREATMENT OF UNTREATED NON-GERMINAL CENTER B-CELL SUBTYPE DIFFUSE LARGE B-CELL LYMPHOMA WITH EXTRANODAL INVOLVEMENT.
por: Caixia, LI, et al.
Publicado: (2023)

Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens
por: Jiang, Shiyu, et al.
Publicado: (2020)

Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP
por: Cho, Min-Chul, et al.
Publicado: (2018)

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
por: Kong, Xiaoshuang, et al.
Publicado: (2023)

Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Subtype of the Thyroid
por: Waqar, Syed Hamza Bin, et al.
Publicado: (2021)

Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma
por: Yang, Haiyan, et al.
Publicado: (2022)

Ki67 Proliferation Index in Germinal and Non-Germinal Subtypes of Diffuse Large B-Cell Lymphoma
por: Hashmi, Atif A, et al.
Publicado: (2021)

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
por: Jang, Geundoo, et al.
Publicado: (2011)

GM-CSF enhanced the effect of CHOP and R-CHOP on inhibiting diffuse large B-cell lymphoma progression via influencing the macrophage polarization
por: Zhang, Yu, et al.
Publicado: (2021)

Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma
por: Fu, Zhiying, et al.
Publicado: (2014)

The Modified Glasgow Prognostic Scores as a Predictor in Diffuse Large B Cell Lymphoma Treated with R-CHOP Regimen
por: Kim, Yundeok, et al.
Publicado: (2014)

Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
por: Guo, Wei, et al.
Publicado: (2015)

Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
por: Tariq, Ayesha, et al.
Publicado: (2018)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

DA-REPOCH Versus R-CHOP for the Treatment of Activated B-Cell Subtype Diffuse Large B-Cell Lymphoma: A Community Center Experience
por: Knouse, Phillip, et al.
Publicado: (2020)

4SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed/refractory B cell lymphomas
por: Jiao, Cheng, et al.
Publicado: (2021)

Successful treatment of diffuse large B-cell lymphoma with secondary hemophagocytic lymphohistiocytosis by R-CHOP-E regimen: a case report
por: Wu, Ran, et al.
Publicado: (2019)

Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma
por: Samineni, Divya, et al.
Publicado: (2021)

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma
por: Zhang, Qunling, et al.
Publicado: (2016)

R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms
por: Wang, Liang, et al.
Publicado: (2021)

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S, et al.
Publicado: (2016)

5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients
por: Chen, Hang-Yu, et al.
Publicado: (2021)

Sciatic diffuse large B-cell lymphoma with treatment response to CHOP and radiotherapy
por: Shomal Zadeh, Firoozeh, et al.
Publicado: (2023)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

Regulation of germinal center B‐cell differentiation
por: Zhang, Yang, et al.
Publicado: (2016)

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
por: Zhang, Fangwen, et al.
Publicado: (2019)

Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms
por: Yu, Haifeng, et al.
Publicado: (2021)

Germinal center derived B cell memory without T cells
por: Zhang, Yang, et al.
Publicado: (2022)

ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP
por: Liu, Duo, et al.
Publicado: (2017)

Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen
por: Chen, Xing-Gui, et al.
Publicado: (2011)

Radiation Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: What Is the Right Regimen for Palliation?
por: Wright, Christopher M., et al.
Publicado: (2022)

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
por: Zhu, H., et al.
Publicado: (2022)

Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment
por: Zheng, Xiaohui, et al.
Publicado: (2014)

R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
por: Lee, Hong Ghi, et al.
Publicado: (2014)

Construction and Validation of a Novel Nomogram for Predicting the Recurrence of Diffuse Large B Cell Lymphoma Treated with R-CHOP
por: Gong, Yuxi, et al.
Publicado: (2023)

Synergistic effect of oridonin and a PI3K/mTOR inhibitor on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma
por: Qing, Kai, et al.
Publicado: (2016)

Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience
por: Jeong, Jae-Uk, et al.
Publicado: (2017)

The international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP
por: Wei, Xiaolei, et al.
Publicado: (2017)

Clinical efficacy and tumour microenvironment influence of decitabine plus R‐CHOP in patients with newly diagnosed diffuse large B‐Cell lymphoma: Phase 1/2 and biomarker study
por: Zhang, Mu‐Chen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vqghtufdi1vom0j73n9gu2r80e